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ANGPTL4Cardiac hypertrophy is characterised by an imbalance between lipid uptake and fatty acid β-oxidation leading to
an accumulation of lipids, particularly triacylglycerol (TAG). It is unclear whether uptake mechanisms such as
lipoprotein lipase (LPL) can be attenuated to diminish this uptake. Rats were cold acclimated to induce cardiac
hypertrophy and increase cardiac LPL. Lipid uptake and metabolism were altered by feeding a ‘Western-style’
high fat diet (WSD) or feeding oxfenicine (2 g/L) in the drinking water. Diastolic stiffness (increased
volume change/unit pressure change) was induced in hypertrophied hearts for rats fed WSD (Pb0.05) or
WSD+oxfenicine (Pb0.01), although absolute performance of cardiac muscle, estimated from stress–strain
calculations was unchanged. Cold acclimation increased cardiac endothelial LPL (Pb0.05) but this was dimin-
ished following oxfenicine. Following WSD LPL was further decreased below WSD-fed control hearts (Pb0.05)
with no further decrease by oxfenicine supplementation. A negative correlation was noted between plasma
TAG and endothelial LPL (correlation coefﬁcient=−0.654; Pb0.001) but not cardiac TAG concentration. Tran-
script levels of angiopoietin-like protein-4 (ANGPTL4) were increased 6-fold by WSD (Pb0.05) and increased 15-
fold following WSD+oxfenicine (Pb0.001). For CA-hearts fed WSD or WSD+oxfenicine ANGPTL4 mRNA levels
were preserved at chow-fed levels. VLDLR protein levels were increased 10-fold (Pb0.01) by CA. ANGPTL4 protein
levels were increased 2-fold (Pb0.05) by WSD, but restored following oxfenicine. For CA-hearts WSD increased
ANGPTL4 protein levels 3-fold (Pb0.01) with WSD+oxfenicine increasing ANGPTL4 protein 4-fold (Pb0.01).
These data suggest that endothelial LPL levels in the heart are altered tomaintain FA ﬂux andmay exploit ANGPTL4.
© 2011 Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The heart has a high and unremitting demand for energy and relies
on metabolic ﬂexibility to derive this energy from the prevailing
substrates present in plasma [1]. In the fed (postprandial) state the
majority of energy is derived from lipids in the diet. These are principal-
ly transported in the form of chylomicrons andmust be assimilated into
themyocardium through lipoprotein lipase, an endothelium-expressed
enzyme that controls the transport of triacylglycerol-derived fatty acids
(FA) into the cardiomyocyte across the endothelium. Chylomicrons
may provide the majority of FA-derived energy as measured for the in
vitro perfused myocardium [2] and in the whole animal [3]. LPL is intri-
cately coupled to the very-low-density lipoprotein receptor (VLDL-
receptor) and investigations have demonstrated the potency of the
VLDL-receptor to bind lipoproteins and act as an anchor [4], facilitating
the lipolysis of lipoprotein particles to release NEFA and thus generate a
high local concentration at the endothelium. The VLDL-receptor may
also facilitate uptake of core lipids from lipoproteins [5]. Further studies
have also demonstrated the ability of VLDL-receptor to bind LPL+44 121 4146919.
-NC-ND license.directly, and elegant experiments have proposed the exploitation of
this mechanism for the translocation and subsequent re-expression of
LPL from the cardiomyocyte, across the endothelium to the luminal
surface of capillaries [6]. Indeed, the VLDL-receptor-null mouse has
low herparin-releasable LPL (hrLPL) activity in muscle and heart [7].
Yet the steps controlling the presentation of LPL at the endothelial sur-
face are unclear.
We have recently demonstrated that chronic activation of AMPK
with metformin increased the endothelial localisation of LPL [8]. Given
the assertion that the hypertrophied heart is relatively energy-
depleted and the subsequent activation of AMPK increases the uptake
of substrates (both glucose and fatty acids) to offset this ATP shortfall,
suggests that chronic activation of AMPK, as occurs in cardiac hypertro-
phy [9], and may result in accumulation of lipid in the myocardium
through increased translocation of LPL to the capillary endothelium.
This may be exacerbated further by the decline in fatty acid oxidation
noted for the hypertrophed heart [10]. Intracellular lipid content
depends on the balance of uptake (both NEFA and LPL-mediated TAG
uptake) and the rate of FA oxidation. Lipid accumulation is believed to
contribute to lipotoxicity and alters the sensitivity of the myocardium
to catecholamine-mediated inotropy [11], altered insulin signalling
[12] and triggers apoptosis [13]. However, experimental models have
tended to rely upon constitutive over-expression of LPL at the luminal
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altering the transfer of LPL to the capillary endothelium is functional
in the intact myocardium to prevent the ectopic accumulation of lipid
in the cardiomyocyte. Multiple sites are potential targets including the
synthesis of LPL, the translation of mRNA to functional enzyme or the
transfer of functional LPL from the cardiomyocyte to the endothelial
surface of capillaries.
We have exploited the cold-acclimated rat as amodel for physiolog-
ical cardiac hypertrophy that does not show impaired β-oxidation of
fatty acids [14] to investigate for theﬁrst time the inﬂuence of hypertro-
phy on the expression of LPL and VLDL-receptor proteins and quantify
the activity of cardiac lipoprotein lipase following changes to the lipid
milieu in the intact rat. Lipid accumulation was initiated using either a
Western-style high fat diet and/or the chemical inhibitor of carnitine
palmitoyl-transferase 1 (CPT1), oxfenicine. Cardiac performance was
estimated and the expression and activity of LPL enzyme quantiﬁed to
determine whether altering substrate availability can change the
presentation of LPL at the cardiac capillary surface.
Materials and methods
Materials
3H-[9,10]-triolein were purchased from Amersham Biosciences
(Chalfont, UK). Fatty acid-free bovine albumin and all buffer salts
were purchased from Sigma (Poole, UK). All solvents were ANALAR
grade and purchased from Fisher Scientiﬁc (Loughborough, UK).
Kits for the measurement of plasma and tissue triacylglycerol and
cholesterol were obtained from Randox (Crumlin, Antrim UK). Ven-
tricular balloons were constructed ‘in house’ using Saran Wrap poly-
thene ﬁlm. RT-PCR reagents were obtained from Applied Biosystems
(Carlsbad, CA, USA) (assay on demand VLDLR – Rn01498163_m1:
LPL – Rn01446981_m1: ANGPTL4 – Rn01528817_m1: Internal refer-
ence GAPDH – 4308313).
Methods
Animals
Animals were maintained in accordance with the UK Home Ofﬁce,
Animal Scientiﬁc Procedures Act (1986) and the experiments were
approved by the University of Birmingham Ethical Review Committee.
Animals were housed at 22 °C 12 h light/12 h dark with ad libitum
access to food and water.
Cold acclimation
Animals were acclimated to cold as previously outlined [14,15].
Brieﬂy rats (60gm) were housed in pairs in an environmental chamber
with minimal wood-chip cage bedding and ad libitum access to both
food and water. The chamber was cooled from 21 °C to 4 °C over a
period of 4 weeks, with day length reduced from 12 h light/dark to
1 h light/23 h dark over the same period. After this 4 week period rats
were randomised into separate groups and maintained on either a
chow diet or a Western-style high fat/sucrose diet (WSD-824503,
Special Diet Services, Lilico Biotechnology, UK) for a further 2 weeks.
These two groupswere further sub-divided into groups receiving either
tap water to drink or water supplemented with 4-hydroxy-phenyl-gly-
cine (Oxfenicine — 2 g/L) [16], giving a total of 4-experimental groups.
These groups were duplicated using control animals maintained
under standard conditions of temperature and day length, but supple-
mented with either chow diet orWSD and water or oxfenicine solution
(2 weeks–2 g/L oxfenicine).
Tissue isolation and heart perfusion
Animalswere prepared surgically following 6 weeks of diet/temper-
ature manipulation as outlined previously [17]. Brieﬂy, anaesthesia was
inducedwith isoﬂurane (~4% isoﬂurane in oxygen). Bloodwas collectedin a heparinised syringe from inferior vena cava and following thoracot-
omy, hearts were excised. Hearts were perfused in retrograde fashion,
as outlined previously [17]. A small ﬂexible non-elastic balloon was
inserted into the left atrium through the mitral valve and into the left
ventricle. This ﬂuid-ﬁlled balloonwas attached to a ﬁne plastic catheter
and connected to a pressure transducer (MEMSCAP, Skoppum, Nor-
way) and a graduated syringe (0–1000 μl: Hamilton, Nevada, USA).
Hearts were maintained at 37 °C and perfused at a constant pressure
(100 cm H2O) with a Krebs–Henseleit crystalloid medium supplemen-
ted with glucose (10 mM) and CaCl2 (1.3 mM) gassed with oxygen/
CO2 (95:5). Developed pressure was measured following isovolumic
contraction of the ﬂuid-ﬁlled balloon and recorded to computer using
a digital interface (AD Instruments, Chalgrove, Oxford, UK).
Ventricular performance
Ventricular performance was estimated, as outlined previously [17].
Balloon volume was increased in incremental steps (50 μl) and devel-
oped pressure was recorded in real time. Pressures were allowed to
stabilise until diastolic pressure remained constant before initiating
further increases in balloon volume. Incremental increases in balloon
volume were performed until the peak systolic pressure developed
exceeded 200 mmHg. The balloon was then deﬂated and the process
repeated. Coronary ﬂow was estimated from timed collections of a
known volume of perfusate and expressed as volume/unit time/unit
mass of cardiac tissue. Ventricular performance was calculated off-line
following the experiment using computer analysis software (Chart
Version 5.0, AD Instruments, Chalgrove, Oxford, UK). Heart rate, systolic
pressure and diastolic pressure were measured and hence developed
pressure calculated. Rate of change of pressure (+dP/dt)was calculated
from the maxima of ﬁrst order derivative of pressure trace. Rate
pressure product (RPP) was calculated at each balloon volume as the
product of heart rate (bpm) x developed pressure (mmHg).
Contractile reserve
For selected hearts, ventricular balloon volumewas adjusted to give
a stable end-diastolic pressure (20 mmHg). Estimates of cardiac perfor-
mance were made prior to, and after, addition of the sympathomimetic
inotrope isoprenaline (ﬁnal concentration 10 μM) to the perfusate.
Increases in developed pressure and rate of pressure development
were estimated once stable cardiac performance was achieved.
Cardiac stress–strain calculations
Cardiac stress–strain calculations were undertaken as detailed in
Woodiwiss and Norton [18] with modiﬁcations [19]. Brieﬂy, LVEDV
was estimated as detailed previously for perfused hearts (Cheng and
Hauton 2008). LV wall volume was calculated from LV wall wet mass
x 0.943 [18]. Data was represented as gradients of linearised stress–
strain relationships, following linear regression analysis, for animals
within the same treatment group.
Total lipid extraction
Total cholesterol, phospholipid and triglycerideswere also extracted
from liver and heart tissue as described previously [15]. Brieﬂy, aliquots
(100 mg) of tissue powder were extracted with methanol:chloroform
(1:2). Extractswere evaporated to dryness and resuspended in absolute
ethanol. Hepatic and cardiac TAG, phospholipid and cholesterol were
measured using commercial kits.
Lipid inﬁltration
Lipid inﬁltrationwas estimated from tissue sections stained with Oil
Red ‘O’ [20]. Brieﬂy, frozen sections (10 μm)were air-dried and ﬁxed in
formaldehyde solution (3.7%w/v). Sections were rinsed in distilled
water and stained with Oil Red ‘O’ (300 mg/ml in 36% v/v triethyl
phosphate in distilled water). Sections were de-stained in distilled
water before mounting. Lipid droplets were visualised by ﬂuorescence
microscopy with Texas red ﬁlter (×200 magniﬁcation). 3 non-
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Zeiss Axioskop microscope and proprietary software. Images were ana-
lysed using Image J software (NIH). Images were split into primary col-
ours, the red channel converted to binary image and smoothing
function employed to remove individual ‘stray’ pixels. The remaining
regions were quantiﬁed for mean particle size and coverage of section.
Lipoprotein lipase activity
Lipoprotein lipase (LPL) activity was measured as previously
described [8]. Brieﬂy, separate groups of hearts from chow and
WSD-treated rats were perfused with Krebs–Hensleit medium contain-
ing glucose (10 mM) and CaCl2 (1.3 mM) as outlined above. Perfusion
was maintained initially in non-recirculating mode to wash out
erythrocytes. Recirculating perfusion was established and maintained
for 5 min, after which heparin(10U/ml ﬁnal concentration) was added
and recirculated for a further 2 min. Samples of perfusate were isolated
and frozen in liquid nitrogen. Cardiac tissue was then snap-frozen in
liquid nitrogen and cardiacmass noted. Aliquots of post-heparin perfus-
ate and acetone-dried heart powders (10 mg) were reacted with tria-
cylglycerol emulsion (ﬁnal concentration 5.6 mM) pre-labelled with
3H-[9,10]-triolein supplemented with human plasma (ratio plasma to
ﬁnal reaction volume 1:6) as a source of Apolipoprotein CII. Reactions
were carried out in Tris.HCl buffer (0.1 M, pH=8.0) supplemented
with fatty acid free bovine albumin (ﬁnal concentration 2.0%w/v).
Incubations were carried out at 37 °C and activities were expressed
per unit mass of cardiac tissue. Total cardiac LPL activity was estimated
as the sum of tissue residual LPL and heparin-releasable LPL activity.
Estimation of tissue sphingomyelin
Tissue sphingomyelin contents were estimated by the method of
Hojjati and Jiang [21] from ethanol extracts of powdered tissue. Brieﬂy,
samples and standards (0.5 mg/ml in ethanol)were incubated in reaction
mixture comprising Tris.HCl buffer (50 mM, 0.66 mM CaCl2, pH=8.0);
sphingomyelinase (0.5U/ml); alkaline phosphatase (10U/ml); choline
oxidase (0.5U/ml); peroxidise (20U/ml); 4-aminoantipyrine (0.73 mM)
and DAOS (0.73 mM). At termination absorbance was quantiﬁed
(595 nm) and concentration calculated with reference to standard
curve.
Serum lipids
Serumwas collected for all groups and used tomeasure total choles-
terol (Randox cholesterol reagent), triglycerides (Randox triglyceride
reagent), glucose (Thermo-Electron glucose kit). All assays were
quantiﬁed as outlined in kit instructions using a 96-well plate analyser.
Gene expression
Two-step RT-PCRwas performed using 1 μg of RNA, randomhexam-
ers and Multiscribe reverse transcriptase enzyme (Applied Biosystems,
UK). An ABI 7500 real time PCR machine was used to quantitate rat
transcripts using speciﬁc primer pairs and probes (Applied Biosystems,
USA). Real time expression assays speciﬁc for VLDLR, ANGPTL4 and
GAPDHwere purchased as ‘assay on demand’ from Applied Biosystems,
UK. All samples were normalised to GAPDH transcript levels and data
presented as arbitrary units (AU) calculated as AU=1000x2ΔΔCt.
Immunoblotting for proteins
Western blot analysis was carried out on frozen whole heart tissue
following removal of adipose tissue and atria. StandardWestern immu-
noblotting techniques were used for the detection and estimation of
relative amounts of ANGPTL4 or VLDLR (20–100 μg protein). Brieﬂy,
cardiac tissue (50 mg) was powdered in liquid nitrogen and extracted
with Radio-immunoassay Precipitation Assay (RIPA) buffer containing
protease inhibitors, before centrifugation and recovery of the superna-
tant. The PVDF-membranes were probed with antibodies speciﬁc for
VLDLR (Santa Cruz — dilution 1:2000), mouse monoclonal ANGPTL4
(1–2000 dilution). Appropriate HRP-linked secondary antibodies wereused and membranes developed using enhanced chemiluminesence
(ECL) detection (Roche). Densitometry of Western blots was estimated
using ImageJ software (NIH). Protein expression was corrected for the
expression of an internal control (tubulin).
Statistical analysis
Statistical analysis was carried out using 2-way ANOVA analysis
where appropriate to compare the effect of diet or cold acclimation.
Data represents mean±standard deviation. Correlation coefﬁcients
were calculated using Spearmans rank method and ‘best ﬁt’ was esti-
mated assuming a linear relationship. Where appropriate statistical
signiﬁcance was calculated using Student's ‘t’ test.
Results
Post mortem
Cold acclimation had no effect on the growth of rats and oxfenicine
or WSD did not alter growth (Table 1). CA increased cardiac mass for
chow-fed and WSD rats (Pb0.001 for both; Table 1) yet supplementa-
tion of chow-fed CA rats with oxfenicine restored cardiac mass to con-
trol levels (NS; Fig. 1). By contrast, for CA-WSD rats, oxfenicine
decreased cardiac mass, but did not restore it toWSD-fed control levels
(Pb0.05; Table 1).
Plasma glucose was preserved for all chow-fed rats, irrespective of
cold acclimation or supplementation with oxfenicine (NS; Table 1).
WSD signiﬁcantly increased plasma glucose for untreated rats
(Pb0.01; Table 1) but this was restored to chow-fed levels by either
CA or oxfenicine treatment (NS; Table 1).
Cold acclimation decreased plasma TAG for chow-fed animals
(Pb0.05; Table 1) however this was restored following supplementa-
tion with oxfenicine (NS; Table 1). WSD increased plasma TAG 2-fold
for untreated and oxfenicine-supplemented rats (Pb0.01 and Pb0.05
respectively; Table 1). For CA-rats, WSD increased plasma TAG 6-fold
(Pb0.001; Table 1) and thiswasmaintained following supplementation
of CA-WSD rats with oxfenicine (Pb .001, Table 1).
Analysis of hepatic lipids showed that oxfenicine decreased hepatic
TAG content for chow-fed rats (Pb0.05; Table 1). CA halved hepatic TAG
content (Pb0.001; Table 1) however supplementation with oxfenicine
for CA-rats restored hepatic TAG (NS; Table 1). Animals maintained
on WSD had increased hepatic TAG content, irrespective of treatment
with CA, Oxfenicine or CA+oxfenicine in combination (Pb0.001 for
all; Table 1).
Cardiac performance
Estimate of cardiac performance with intraventricular balloon
revealed that neither WSD nor WSD+oxfenicine had any effect of
diastolic performance for hearts isolated from control animals (Supple-
mental Fig. 1A & 1B). However, for CA rats,WSD decreased the diastolic
stiffness of the left ventricle (Supplemental Fig. 1 Pb0.05 for CA;
Pb0.01 for CA+Oxfenicine) for CA rats fed WSD (Supplemental Fig.
1C) or WSD+oxfenicine (Supplemental Fig. 1D). For chow-fed rats
stiffness was increased by oxfenicine and CA alone (Pb0.05 for both,
Fig. 1A). However WSD returned diastolic stiffness for CA hearts to
control levels (NA, Fig. 1A). Investigation of the relationship between
plasma TAG and diastolic stiffness from pooled data indicated a nega-
tive correlation between plasma TAG and LV diastolic stiffness
(Fig. 1B, coefﬁcient=−0.547; Pb0.001). However estimation of LV
stress–strain relationship, measured as the gradient of the linear
regression of stress–strain relationship (Supplemental Fig. 2), showed
that WSD did not alter the LV stress–strain relationship for control,
oxfenicine-treated rats, CA rats or CA rats+Oxfenicine (Fig. 2).
However, comparison of the effect of CA (Fig. 2) on stress–strain
revealed that CA decreased the gradient of the stress–strain
Table 1
Post mortem data collected from control and cold-acclimated rats fed chow or a western-style high fat diet. Data represents MEAN±SD (n=6). Statistical signiﬁcance represented
as signiﬁcantly different from untreated controls * Pb0.05, ** Pb0.01, *** Pb0.001; effect of oxfenicine-treatment+Pb0.05, ++ Pb0.01, +++ Pb0.001; Effect of Western-style
diet †Pb0.05, ††† Pb0.001.
Control — chow diet Western diet
MEASUREMENT Untreated Oxfenicine Cold
acclimated
Cold acclimated
+Oxfenicine
Untreated Oxfenicine Cold
acclimated
Cold acclimated
+Oxfenicine
Body mass (g) 298±8 370±8 283±18 290±22 302±16 322±21 291±22 302±21
Heart mass (g) 1.29±0.1 1.46±0.2 1.58±0.16⁎⁎⁎ 1.32±0.09 1.37±0.08 1.40±0.2 1.74±0.10⁎⁎⁎ 1.52±0.08⁎+††
Heart–body mass ratio (%) 0.43±0.04 0.43±0.03 0.56±0.06⁎⁎ 0.45±0.04++ 0.45±0.02 0.39±0.03 0.60±0.03⁎⁎⁎ 0.51±0.03+++†
Plasma glucose (mM) 9.25±0.56 8.06±1.18 8.96±1.56 9.13±1.44 11.46±1.49†† 7.60±1.56 10.54±1.73 12.10±1.39††
Plasma triacylglycerol (mM) 0.90±0.23 1.36±0.06 0.62±0.13⁎ 0.78±0.39 2.07±0.64†† 2.80±1.20† 3.82±0.97⁎⁎††† 5.02±0.80⁎⁎⁎+†††
Hepatic TAG (μmoles/g) 10.2±1.82 7.15±0.93+ 5.69±1.71⁎⁎⁎ 7.28±3.73 18.51±1.96††† 20.23±3.04††† 18.27±3.39††† 18.31±2.70†††
Hepatic cholesterol (mg/g) 2.56±0.22 1.05±0.32+++ 2.64±0.30 2.16±0.30 4.08±0.67††† 2.15±0.88†+++ 3.49±0.54††† 3.07±0.86†††
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was unaffected by WSD (Pb0.01 for CA, Pb0.01 for CA+WSD Fig. 2).
Isoprenaline-induce inotropy
Cardiac performance at ﬁxed end-diastolic pressure (EDP) (estimat-
ed as developed pressure, rate-pressure product or+dP/dt) was0
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Fig. 1. Effects of western-style high fat diet or oxfenicine on diastolic stiffness for normal
or hypertrophied rat hearts. A) Diastolic stiffness was estimated from the gradient of
linear regression of diastolic performance curve for pressure values greater than zero at
the point the regression line bisected the balloon volume at diastolic pressure=Zero.
Hearts were perfused with Krebs–Hensleit buffer at ﬁxed coronary perfusion pressure
(100 cmH2O)with pressure estimated using non-elastic balloon placed in the left ventri-
cle. For further details see methods. B) Correlation between plasma triacylglycerol (TAG)
and diastolic stiffness for perfused hearts.Plasma TAG concentrations were estimated
from venous blood samples collected under terminal anaesthesia. Data represents
MEAN±SD (n=6 hearts/group). Best ﬁt was determined from linear regression of the
data points giving the equation Y=−0.03851x+0.711144. Correlation was quantiﬁed
using Spearman's rank test, with signiﬁcance estimated by ‘t’ test. Statistical signiﬁcance
is represented as: effects of oxfenicine+Pb0.05; effect of cold acclimation * Pb0.05; effect
of western-style diet † Pb0.05, †† Pb0.01.unaffected by oxfenicine or CA for chow-fed rats, however combination
of CA+oxfenicine increased developed pressure 25% (Pb0.05),
increased dP/dt 40% (Pb0.01) and increased RPP 25% (Pb0.01;
Table 2). Addition of isoprenaline increased developed pressure
(Pb0.01), RPP (Pb0.05) and dP/dt (Pb0.01) for chow-fed hearts and
this increase was preserved following oxfenicine treatment (Pb0.01;
Table 2). CA abolished the increase in cardiac work for chow-fed rats
(NS; Table 2) but supplementation of CA-rats with isoprenaline
augmented developed pressure 20% (Pb0.05), RPP 30% (Pb0.05) and
dP/dt 50% (Pb0.01; Table 2).
For untreated rats fed WSD isoprenaline also augmented cardiac
work (Pb0.01; Table2), however with addition of oxfenicine or CA
no increase in cardiac work was noted following addition of isopren-
aline (NS; Table 2). Combination of CA+oxfenicine for WSD-rats
restored the response to isoprenaline, increased developed pressure
50% (Pb0.001), RPP 100% (Pb0.001) and dP/dt 2-fold (Pb0.001) for
corresponding CA-rats (Table 2).Cardiac lipid concentrations
Irrespective of treatment, cardiac phospholipid and sphingomyelin
contents were unchanged by either CA, WSD or oxfenicine alone or in
combination (Fig. 3). WSD alone had no effect on cardiac TAG content0
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Fig. 2. Effect of cardiac hypertrophy and western diet on the intrinsic performance of rat
left ventricle. Performancewas estimated from the gradient of the linearised stress–strain
relationship. Best ﬁt was determined from linear regression of the data points and plotted
as rend line through the appropriate points (see Supplemental Fig. 1). Cardiac stress and
strain were calculated as outlined in the methods. Data represents MEAN±SD (n=6
hearts/group). Statistical signiﬁcance is represented as: effect of cold acclimation **
Pb0.01.Effect of cardiac hypertrophy and western diet on the intrinsic performance of
rat left ventricle. Performance was estimated from the gradient of the linearised stress–
strain relationship. Best ﬁt was determined form linear regression of the data points and
plotted as rend line through the appropriate points (see Supplemental Fig. 1). Cardiac
stress and strain were calculated as outlined in the methods. Data represents MEAN±SD
(n=6 hearts/group). Statistical signiﬁcance is represented as: effect of cold acclimation **
Pb0.01.
Table 2
Effects of Cold Acclimation and Isoprenaline on cardiac performance in Langendorff-perfused rat hearts. Hearts were perfused at constant pressure (100 cm H2O) and performance
measured with intraventricular balloon. Diastolic pressure was set at 20 mmHg. Data represents MEAN±SD (n=6). Statistical signiﬁcance represented as: effects of isoprenaline *
Pb0.05; ** P>0.01: effects of oxfenicine+Pb0.05; ++ Pb0.01; +++Pb0.001.
Group Control Isoprenaline (10 μM)
Developed pressure
(mmHg)
+dP/dtmax
(mmHg/s)
Rate-pressure product
(mmHg/min)
Developed pressure
(mmHg)
+dP/dtmax
(mmHg/s)
Rate-pressure product
(mmHg/min)
Chow diet
Control 59±12 1053±216 16437±3145 86±6⁎⁎ 1903±341⁎⁎ 25052±4465⁎
Oxfenicine 86±10 1323±142 19166±2086 103±11⁎ 1771±199⁎⁎ 25723±2015⁎⁎⁎
Cold-acclimated 59±9 941±157 14362±2573 58±8 1274±226 18394±3408
Cold Acclimated+Oxfenicine 75±7+ 1402±241++ 20330±2822++ 90±11⁎+++ 2106±402⁎⁎++ 26247±4834⁎+
Western Diet
Control 60±9 990±185 14724±3205 74±3⁎⁎ 1389±194⁎⁎ 18370±1678⁎⁎
Oxfenicine 82±15 1313±287 18604±3183 92±11 1563±213 22525±2214
Cold-acclimated 52±11 867±211 11344±3208 56±13 1089±267 13370±3820
Cold acclimated+oxfenicine 86±8+++ 1607±286++ 19766±3847++ 105±11⁎+++ 2424±297⁎⁎+++ 27329±2366⁎⁎+++
631D. Hauton, G.M. Caldwell / Biochimica et Biophysica Acta 1821 (2012) 627–636for untreated rats (NS; Fig. 3). For chow-fed rats, oxfenicine increased
cardiac TAG content 2-fold (Pb0.05; Fig. 3). However when chow-fed
CA rats were supplemented with oxfenicine, cardiac TAG levels were
unchanged (NS; Fig. 3). For WSD rats, oxfenicine supplementation
increased cardiac TAG 3-fold (Pb0.01; Fig. 3) when compared to
WSD-fed control rats. CA had no effect of cardiac TAG levels in either
chow-fed or WSD-fed rats. For CA rats fed WSD, oxfenicine increased
cardiac TAG levels 2-fold (Pb0.05; Fig. 3).0
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with chow-fed CA rats (Pb0.001, Fig. 4A) and 20% lower that
WSD-fed control rats (Pb0.05, Fig. 4A). For CA rats fed WSD
supplemented with oxfenicine hrLPL activity decreased 20% below
WSD-fed control rats (Pb0.05; Fig. 4A) and 20% below chow-fed CA+
oxfenicine rats (Pb0.05; Fig. 4A).
For chow-fed rats, CA increased tissue residual LPL (trLPL) 40%
(Pb0.05; Fig. 4B). Oxfenicine had no effect on trLPL for chow-fed
rats, however for chow-fed CA rats, oxfenicine decreased trLPL 40%
compared to corresponding CA rats (Pb0.05; Fig. 4B). For untreated
controls, WSD had no effect on trLPL (NS; Fig. 4B). Furthermore, for
CA rats fed WSD, trLPL was also unchanged (NS; Fig. 4B). Treatment
of CA-WSD rats with oxfenicine halved trLPL compared with
CA-WSD rats (Pb0.05; Fig. 4B). Investigation of the factors affecting
the tissue levels of hrLPL revealed a negative correlation between plas-
ma TAG and hrLPL for pooled data (correlation coefﬁcient=−0.654;
Pb0.001; Fig. 5A) However, no correlation between cardiac tissue TAG
levels and hrLPL (correlation coefﬁcient=−0.01; Pb0.001; Fig. 5B).
Transcript levels
All mRNA levels were expressed as fold change from untreated
chow-fed rat hearts. Irrespective of treatment, whole heart levels of
VLDLR transcript were unaltered by any treatment used (NS; Fig. 6A).
For LPL, transcript levels were unchanged for hearts from chow-fed
rats when supplemented with oxfenicine or cold acclimated, alone or
in combination (NS for all; Fig. 6B). ForWSD-fed rats, neither oxfenicinenor CA alone changed LPL mRNA levels (NS for both; Fig. 6B): however
in combination LPL mRNA levels were halved (Pb0.01; Fig. 6B). For
chow fed rats, ANGPTL4 transcript levelswere unchanged by oxfenicine
or CA, alone or in combination (NS; Fig. 6C). WSD increased ANGPTL4
mRNA levels 6-fold compared to chow-fed controls (Pb0.05; Fig. 6C).
Supplementation of WSD-rats with oxfenicine increased ANGPTL4
mRNA levels 15-fold relative to chow-fed controls (Pb0.001; Fig. 6C)
and 2-fold over WSD-fed control rats (Pb0.01; Fig. 6C). ANGPTL4
mRNA levels were unchanged for CA rats fed WSD or for CA-WSD rats
receiving oxfenicine (NS for both; Fig. 6C).
Protein expression
All immunodetectable protein levels were expressed as fold change
from untreated chow-fed rat hearts. Irrespective of treatment, CA
increased VLDLR protein levels 8-fold (Pb0.01; Fig. 7). This was unaf-
fected by supplementation with oxfenicine or WSD (NS; Fig. 7). For
chow-fed rats, ANGPTL4 protein levels were unchanged by oxfenicine
or CA, alone or in combination (NS for both; Fig. 7). WSD increased
ANGPTL4 levels 2-fold compared to chow-fed controls (Pb0.05;
Fig. 7). However supplementation ofWSD-ratswith oxfenicine restored
ANGPTL4 to untreated levels (NS; Fig. 7). For WSD rats, CA increased
ANGPTL4 3-fold compared to untreated control (Pb0.05; Fig. 7) and
supplementation of WSD-CA rats with oxfenicine increased ANGPTL4
protein 4-fold compared to untreated controls (Pb0.05; Fig. 7).
Discussion
We investigated the effects of a variety of interventions designed to
alter lipid metabolism and myocardial TAG handling and performance.
We demonstrate that short-term feeding of WSD led to high plasma
TAG concentration that was further increased following cold
00.5
1
1.5
2
2.5
3
R
el
at
iv
e 
ex
pr
es
si
on
 (A
U)
Very-Low-Density Lipoprotein Receptor
Chow High fat
A
B
C
0
0.5
1
1.5
2
2.5
3
R
el
at
iv
e 
Ex
pr
es
si
on
 (A
U) Lipoprotein lipase
n=3
n=3
0
2
4
6
8
10
12
14
16
18
20
Con Con+Ox CA CA+Ox Con Con+Ox CA CA+Ox
Con CA CA+Ox Con CA CA+Ox
Con Ox Ox
Ox Ox
CA CA+Ox Con CA CA+Ox
R
el
at
iv
e 
ab
u
n
da
nc
e
(A
U)
n=4Angiopoietin-like protein-4
++
**
Fig. 6. RT-PCR gene transcript levels for cardiac A) very-low-density lipoprotein receptor,
B) lipoprotein lipase and C) angiopoietin-like protein 4. RT-PCRwas performed using 1 μg
of RNA. Real time expression assays speciﬁc for VLDLR, ANGPTL4 and GAPDH were
purchased as ‘assay on demand’ from Applied Biosystems, UK. All samples were normal-
ised to GAPDH transcript levels and data presented as arbitrary units (AU) calculated as
AU=1000x2ΔΔCt. Data represents MEAN±SD (n=3–4 hearts/group). Statistical
signiﬁcance is represented as: effect of cold acclimation ** Pb0.01; effects of oxfenicine
++ Pb0.01; effect of western-style diet † Pb0.05, ††† Pb0.001.
633D. Hauton, G.M. Caldwell / Biochimica et Biophysica Acta 1821 (2012) 627–636acclimation, and contributed to cardiac dysfunction in the hypertro-
phied heart. This was characterised as a change in diastolic stiffness of
the left ventricle that was not a result of changes to the intrinsic perfor-
mance of the muscle (estimated as stress–strain). The correlation of
diastolic stiffnesswith plasma TAG concentrationwasmodest, however
no correlation was noted with myocardial TAG content (data not
shown). Furthermore, we show that inhibition of lipid oxidation with
oxfenicine led to TAG accumulation in the myocardium. In addition,
the activity of LPL for hypertrophied hearts was subject to regulation
by components of a ‘Western-style’ high fat diet, activity decreased by
the diet, possibly as a consequence of increased levels of ANGPTL4
protein leading to decreased synthesis of active enzyme protein. This
down-regulation of hrLPL activity was so profound as to prevent the
lipid accumulation anticipated and thus mitigate against further lipid-
induced cardiac dysfunction. Interestingly, there appears to be a discon-
nection between ANGPTL4 mRNA levels and transcription of protein,indicative of a dynamic system ‘sensing’ the availability of lipid possibly
involving PPAR [22].
Diastolic stiffness of the LV was maintained for animals fed a chow
diet yet showed declines in performance for hypertrophied hearts
when maintained on WSD. Investigation of the impact of plasma TAG
indicates that a modest negative correlation between diastolic stiffness
and plasma TAG, associating increased plasma lipid levels with de-
creased cardiac mechanical performance. However it was unclear
whether this was a direct cause of altered performance of the muscle.
Estimation of the stress–strain relationship for the LV indicated that
for all hearts WSD had no effect on the stress–strain relationship al-
though CA led to decreasedmechanical performance. This is most likely
a result of the poor performance coupledwith the increasedmass of the
heart associatedwith CA previously noted [14] and is not a result of high
fat feeding directly. Previous experiments illustrate that WSD may in-
duce decreases in cardiac performance for control rats following long
duration feeding [23]. Although, following hypertrophy changes may
be faster — high fat diet inducing contractile dysfunction in hearts fol-
lowing aortic banding in as little as 7-days [24] and may be attributable
to increased cardiac hrLPL, however this was not measured. This is at
odds with longer duration experiments that suggest no exacerbation
of cardiac dysfunction by high fat-feeding following pressure patholog-
ical overload hypertrophy [25] implying a temporal correction in lipid
accumulation. Direct inhibition of CPT1 activity with oxfenicine did
not itself induce cardiac hypertrophy or cardiac dysfunction for the con-
trol or worsen hypertrophy or performance in CA-heart, conﬁrming
previous observations for control rats [16].
Estimation of the lipid contents for cardiac tissue suggested that
oxfenicine did inhibit the oxidation of fatty acids, resulting in the accu-
mulation of lipids as TAG. This accumulation was modest, as evident
from the Oil Red ‘O’ staining of myocardium. Moreover, this accumula-
tion is not so severe as to alter tissue phospholipid or sphingomyelin
contents which has been noted for agents that inhibit β-oxidation
such as perhexiline and amiodarone [26]. Of interest was the lack of
effect noted for CA hearts, suggesting that the mechanism for assimila-
tion of lipids into the myocardium may have been under regulatory
control. Given the central role of TAG in cardiac energetics [2] and
that the majority of lipid present in plasma was TAG, the involvement
of LPL in the uptake of TAG was explored.
The functional component of LPL for the assimilation of lipids is the
endothelial compartment that is released following perfusion with
heparin (hr) and this hrLPL is anticipated to increase lipid loading —
particularly associated with decreased β-oxidation. As previously
noted CA led to increased hrLPL in chow-fed rat hearts. This was subse-
quently blunted by oxfenicine. Given the drop in plasma TAG content
noted for chow-fed CA rats thismay reﬂect a need to preserve the inﬂux
rates of FA into the myocardium. Given that FA ﬂux rates through LPL
are governed by either concentration of substrate (in this case TAG) or
the concentration of LPL enzyme, falling ﬂux rates in this case were
overcome through increased enzyme presentation at the endothelium.
One possible origin for the increased rates of lipid assimilation in CA
(hence diminished plasma TAG) is the increased burden of thermogen-
esis, previously noted for the CA rat [15]. For oxfenicine-treated CA rats
the hrLPL levels were normalised as plasma TAG levels were restored,
probably through a decrease in the reliance on TAG as a source of fuel
for thermogenesis. For WSD-fed rats CA decreased hrLPL levels and
the impact of oxfenicine was refractory to WSD, implying that lipid
delivery levels to the myocardium were preserved. Given the increase
in plasma TAG levels for CA rats fed WSD this may be a substrate
concentration-mediated effect.
The strong negative correlation between plasma TAG and hrLPL
levels implies that endothelial presentation of the enzyme may be
dictated by the ﬂux rates of FA entering the cardiomyocyte and thus
ultimately related to the prevailing plasma milieu. Given the continu-
al utilisation of LPL and the loss from the endothelial surface of capil-
laries with the recycling of LPL with remnant lipoprotein particles this
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cholesterol accumulation in the liver following Western diet may be
indicative of such remnant particle recovery [28]. However the
determinants for the frequency of LPL replacement at the endothelium
are unclear, one such trigger is the activation of AMPK by synthetic
agents such as AICAR or perhexiline [29], metformin [8] or ischemia-
reperfusion injury [30]. LPL mRNA expression was unchanged by high
fat-feeding, conﬁrming previous observations [31]. Investigation of
cardiac TAG levels and the resulting hrLPL suggested that in this case
cardiac TAG levels were not the determinant of hrLPL levels. However,
given that the translocation of LPL to the surface of the endothelium
requires multiple steps each with the potential for regulatory control
of this process, we further investigated each step to elucidate the
point(s) of control.
Neither LPL- nor VLDL-receptor mRNA levels were altered by treat-
mentwithWSD or cold acclimation, suggesting that any regulatory step
must be post-translational, the advantage possibly being the rapidity
with which changes could be initiated. Other pathological models of
pressure-overload hypertrophy demonstrate similar increases in LPL
activity yet this was also accompanied by an increase in LPL mRNA
expression and no changes to VLDL-receptor mRNA [32]. It is unclear
whether the changes to metabolism associated with such models of
pressure overload, resulting in TAG accumulation [33], may initiate
changes to VLDL-receptor or LPL expression through ligand-mediated
activation of PPAR [34], although reporter-gene assays suggest that
lipolysis of VLDL by LPL yields ligand activation of PPAR directly [35].ANGPTL4 plays a critical role in the enzyme activity of LPL protein [36]
with ANGPTL4-null mice showing decreased plasma TAG and elevated
post-hpearin plasma LPL activity [37]. WSD led to large increases in
ANGPTL4 transcript levels which were augmented by supplementation
with oxfenicine and abolished following CA. This was unusual given the
recent observations for adipose tissue illustrating an association
between high levels of ANGPTL4 mRNA and low levels of LPL activity
for adipocytes [38]. However, transcript levels do not necessarily dictate
activity of the resulting protein and so immunoblot analysis was
employed to explore changes to protein levels for both VLDL-receptor
and ANGPTL4.
Cold acclimation increased the expression of VLDL-receptor protein,
in contrast to our previous experiments [14]. VLDL-receptor protein
may be closely-associated with the translocation of LPL to the luminal
surface of the capillary endothelium [6], and this discrepancy may be
a result of the longer exposure to chronic cold, our current experiment
sustaining exposure to the lowest temperature (4 °C) for 14-days.
However, direct comparison of this experiment and the previous [14]
imply that levels of hrLPL are similar and thus increased translation of
VLDL-receptor protein does not directly inﬂuence LPL presentation at
the endothelium, merely facilitating the translocation of available
LPL protein. Immunohistochemical analysis of the localisation of
VLDL-receptor suggested this is indeed the case (Supplemental Fig. 3)
with the majority of VLDL-receptor protein localised to apical/capillary
regions of cardiomyocytes. We have previously illustrated the role of
VLDLR in lipoprotein assimilation by the perfused heart, suggesting
635D. Hauton, G.M. Caldwell / Biochimica et Biophysica Acta 1821 (2012) 627–636uptake of lipoproteins in the absence of functional LPL [5]. Mice devoid
of the VLDL-receptor gene show mild hypertriacylglycerolemia and
decreased endothelial presentation of LPL in heart and skeletal muscle
[7] but the direct contribution of VLDLR to this route of uptake may
be small in comparison to LPL-mediated assimilation [7]. Furthermore,
despite noting a 10-fold increase in VLDLR protein levels in these exper-
iments we do not demonstrate a corresponding increase in cardiac TAG
concentration supporting a limited role for VLDLR in direct assimilation
of cardiac lipids for intact heart. Culture of isolated cardiomyocytes
suggested more uniform staining of VLDL-receptor throughout the cell
[39] possibly through a loss of cell polarity, however orientation of
cells within cardiac tissue may be important for the localisaton of
VLDL-receptor.
ANGPTL4 protein levels were increased by WSD-feeding, and
further augmented by CA. High prevailing plasma TAG concentrations
increased the ﬂux of FA into the cardiomyocyte to fuel β-oxidation,
and was blunted following oxfenicine treatment. Yet for CA plasma
TAG levels remained high and thus to maintain the inﬂux of FA hrLPL
levels were attenuated through increased ANGPTL4 protein levels.
Taken together, these observations for both mRNA and protein implied
that upon feedingWSDmRNA transcript levels rose in response toWSD
in the absence of translation to protein suggesting strong feedback
control possibly as a consequence of continual removal of the assimilat-
ed lipid to fuel β-oxidation. However, with further rises in plasma TAG
the ANGPTL4 protein was transcribed decreasing hrLPL, and thus
diminished the ﬂux of FA into the cardiomyocyte. Therefore the stimu-
lus for increases gene transcription is blunted.
Previous experiments document that oxfenicine itself does not alter
cardiac performance but does decrease oxygen consumption for a ﬁxed
cardiac workload [40]. Interestingly, cardiac mitochondria are more
sensitive to the inhibition of CPT1 by oxfenicine than mitochondria
from liver [41]. Dietary supplementation with oxfenicine at levels
used in this experiment increased cardiac lipids in the absence of
increased hepatic accumulation of lipid, even whilst maintenance on
WSD (evidenced by hepatic TAG levels). Agents such as etomoxir that
also inhibit CPT1 led to a decrease in CPT1 activity, despite increasing
CPT1 protein expression, and without altering cardiac TAG content
[42] implying an excess of CPT1 activity in myocardium. Interestingly,
oxfenicine did restore cardiac performance to CA-rat hearts to control
levels, implying that the dysfunction associated with CA was metabolic
in origin. We have previously noted no change in glucose or fatty acid
oxidation rates for the CA rat heart [14] and so improving efﬁciency of
oxygen use (with respect to ATP production) is unlikely to result in
this increased performance. The impact of the high dietary sucrose
present in WSD also cannot be overlooked and this may reduce rates
of glycolysis and increase rates of β-oxidation [43]. Indeed, sucrose
feeding led to both echocardiographic changes and altered calcium
uptake into sarcoplasmic reticulum, but over longer duration than
those used here [44]. WSD alone decreased cardiac performance whilst
increasing oxygen consumption thus contributing to decreased cardiac
efﬁciency [33]. Other possible candidates for impairment of the cardiac
performancemay be the lipids ceramide or diacylglycerol, high levels of
constitutively-active LPL led to accumulation of both lipids in the heart
thatwas ameliorated in part by feedingmyriocin, an inhibitor of de novo
ceramide synthesis, and this restored cardiac efﬁciency [45].
Concluding remarks
Our data does not support the accumulation of TAG as a major
contributor to the aetiology of lipotoxic cardiac dysfunction. In addition,
we suggest that prevailing plasma TAG rather than tissue TAG concen-
tration may alter the level of translocation of LPL to the surface of the
capillary endothelium to preserve fatty acid ﬂux into the heart to fuel
contraction. This is achieved through multiple mechanisms, including
altering the expression of ANGPTL4 protein rather than VLDL-receptor
or LPLmRNA. Build-up of lipids as TAG in the cardiomyocytes is reducedby effective reductions in hrLPL suggesting that feedback autoregulation
may prevent lipotoxicity in physiological hypertrophy. It is unclear
whether lipid accumulation following pathological hypertrophy occurs
through disruption of this process or whether mechanisms such as
AMPK activation can override this mechanism.
Supplementary materials related to this article can be found on-
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